Skip to main content

10 Result(s)

within W. Boogerd Remove this filter

and

  1. No Access

    Article

    Strategies to target drugs to gliomas and CNS metastases of solid tumors

    The treatment for central nervous system metastases of solid tumors and gliomas is limited as the blood–brain barrier (BBB) is an obstacle to systemic therapy. Here, we review the physiochemical properties of ...

    B. Milojkovic Kerklaan, O. van Tellingen, A. D. R. Huitema… in Journal of Neurology (2016)

  2. No Access

    Article

    Cognitive impact of cytotoxic agents in mice

    Adjuvant chemotherapy is associated with changes in cognition in a subgroup of cancer patients. Chemotherapy is generally given as a combination of cytotoxic agents, which makes it hard to define the agent res...

    R. Seigers, M. Loos, O. Van Tellingen, W. Boogerd, A. B. Smit… in Psychopharmacology (2015)

  3. No Access

    Article

    Successful management of brain metastasis from malignant germ cell tumours with standard induction chemotherapy

    Because of possible long-term toxicity, cranial radiotherapy (RT) was withheld as part of standard treatment for brain metastasis (BM) from non-seminomatous germ cell tumours (NSGCT). This study evaluates this...

    R. Gremmer, M. L. J. F. Schröder, W. W. Bokkel ten Huinink… in Journal of Neuro-Oncology (2008)

  4. No Access

    Article

    Prolonged low dose IL-2 and thalidomide in progressive metastatic renal cell carcinoma with concurrent radiotherapy to bone and/or soft tissue metastasis: a phase II study

    Metastatic renal cell cancer is one of the immuno-sensitive tumors. Apart from the immuno-modulating agents IFNα and IL-2, thalidomide has been reported to be effective in this type of cancer. However, bone me...

    J. M. Kerst, A. Bex, H. Mallo, L. Dewit… in Cancer Immunology, Immunotherapy (2005)

  5. Article

    Open Access

    Temozolomide followed by combined immunotherapy with GM-CSF, low-dose IL2 and IFNα in patients with metastatic melanoma

    The purpose of this study is to determine the toxicity and efficacy of temozolomide (TMZ) p.o. followed by subcutaneous (s.c.) low-dose interleukin-2 (IL2), granulocyte–monocyte colony stimulating factor (GM-C...

    G C de Gast, D Batchelor, M J Kersten, F A Vyth-Dreese, J Sein… in British Journal of Cancer (2003)

    Download PDF (184 KB) View Article

  6. No Access

    Article

    Penetration of Idarubicin into Malignant Brain Tumor Tissue

    Anthracyclines are effective in breast cancer and have in vitro cytotoxicity in glioma. In patients with glioma anthracyclines are not effective possibly because the hydrophilic drugs do not reach cytotoxic le...

    W. Boogerd, I.S. Tjahja, M.M. van de Sandt, J.H. Beijnen in Journal of Neuro-Oncology (1999)

  7. No Access

    Article

    Teniposide Sometimes Effective in Brain Metastases from Non-small Cell Lung Cancer

    In a prospective study we have treated 13 patients with brain metastases from non-small cell lung cancer with intravenous teniposide, at a dose of 150 mg/m2 on days 1, 3 and 5 given every 3 weeks on an out-pat...

    W. Boogerd, J.J. van der Sande, N. van Zandwijk in Journal of Neuro-Oncology (1999)

  8. No Access

    Article

    Treatment and outcome of brain metastasis as first site of distant metastasis from breast cancer

    Twenty-eight consecutive patients with breast cancer were analyzedwho presented with a single brain metastasis asfirst site of distant metastasis. The response tosurgery with postoperative radiation therapy (R...

    W. Boogerd, A.A.M. Hart, I.S. Tjahja in Journal of Neuro-Oncology (1997)

  9. No Access

    Article

    Abstracts

    J. M. Derlon MD, M. C. Petit-taboué MD, F. Dauphin PhD… in Journal of Neuro-Oncology (1994)

  10. No Access

    Article

    Brain metastases in breast cancer; natural history, prognostic factors and outcome

    One hundred and thirty seven breast cancer patients with CT scan documented brain metastasis (BM) were reviewed. Occurrence of brain as first site of relapse was associated with adjuvant systemic therapy of th...

    W. Boogerd, V. W. Vos, A. A. M. Hart, G. Baris in Journal of Neuro-Oncology (1993)